TGTian Gao

Tian Gao

*This is an algorithmically generated author record based on publicly available information.

Tian Gao has a total of 78 co-authors. Here are the top co-authors by number of shared publications:

  • Renjun Pei

    Suzhou Institute of Nano-tech and Nano-bionics, Chinese Academy of Sciences

    13 shared publications
  • Wenjing Li

    CAS Key Laboratory of Nano-Bio Interface, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou, 215123, China; School of Nano-Tech and Nano-Bionics, University of Science and Technology of China, Hefei, 230026, China

    5 shared publications
  • Na Sun

    CAS Key Laboratory for Nano‐Bio Interface Suzhou Institute of Nano‐Tech and Nano‐Bionics Chinese Academy of Sciences Suzhou 215123 China

    3 shared publications
  • Pi Ding

    School of Nano-Tech and Nano-Bionics, University of Science and Technology of China, Hefei 230026, China

    3 shared publications
  • Wenjing Li

    CAS Key Laboratory of Nano-Bio Interface, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou, 215123, China

    3 shared publications
  • Zhili Wang

    Department of Orthopedics, Peking Union Medical College Hospital, Beijing, China

    3 shared publications

Latest Publications

  • Deterministic Evolution of Aptamers via a Microfluidic-Integrated Robotic Platform Using Complex Exosomes as Targets

    by Binyao Liu, Yaning Liu, Lei Qiu, Tian Gao, Na Sun, Yecheng Li, Renjun Pei, Haihang Ye, Tingrui Pan

    Exosome (EXO) membrane proteins are attractive biomarkers for liquid biopsy, yet their heterogeneity makes it difficult to develop reliable antibody-based recognition reagents. Aptamers provide high-affinity and highly specific alternatives through the systematic evolution of ligands by exponential enrichment (SELEX), but the nanosized EXOs introduce substantial separation challenges that complicate SELEX workflows. Here, we present DeteRministic Evolution of Aptamers via a Microfluidic-integrated robotic platform (DREAMbot), an automated system engineered to execute multiround EXO-targeted aptamer selection with minimal human intervention. DREAMbot integrates a programmable pipetting robot with deterministic lateral displacement sorting and lipid-assisted magnetic isolation, enabling the automated purification and recovery of EXO-binding aptamers from cell-derived vesicles and molecular contaminants. This robotic-microfluidic workflow faithfully reproduces aptamer enrichment while substantially reducing hands-on burden compared to manual SELEX. Using cell-derived EXOs as targets, DREAMbot identified aptamers with nanomolar dissociation constants and high specificity toward GPC3-positive EXOs from both cultured cells and human serum. With its modular robotic-microfluidic architecture, DREAMbot provides a practical and accessible framework for automated aptamer discovery relevant to liquid biopsy applications.


  • Protein-targeted aptamers in liquid biopsy: from efficient screening to precise cancer diagnosis

    by Wenjuan Xu, Qingyang Liu, Na Sun, Tian Gao, Renjun Pei

    The schematic of early and precise cancer diagnosis based on aptamers selected using SELEX.


  • Purification of Circulating Tumor Cells Based on Multiantibody-Modified Magnetic Nanoparticles and Molecular Analysis toward Epithelial Ovarian Cancer Detection

    by Jialing Ma, Ying Chen, Jing Ren, Tongping Zhou, Zhili Wang, Cheng Li, Lei Qiu, Tian Gao, Pi Ding, Zixin Ding, et al.

    Circulating tumor cells (CTCs) are valuable circulating biomarkers of cancer, which carry primary tumor information and may provide real-time assessment of tumor status as well as treatment response in cancer patients. Herein, we developed a novel assay for accurate diagnosis and dynamic monitoring of epithelial ovarian cancer (EOC) using CTC RNA analysis. Multiantibody-modified magnetic nanoparticles were prepared for purification of EOC CTCs from whole blood samples of clinical patients. Subsequently, nine EOC-specific mRNAs of purified CTCs were quantified using droplet digital PCR. The EOC CTC Score was generated using a multivariate logistic regression model for each sample based on the transcripts of the nine genes. This assay exhibited a distinguishing diagnostic performance for the detection of EOC (n = 17) from benign ovarian tumors (n = 30), with an area under the receiver operating characteristic curve (AUC) of 0.96 (95% CI = 0.91-1.00). Moreover, dynamic changes of the EOC CTC Score were observed in patients undergoing treatment, demonstrating the potential of the assay for monitoring EOC. In conclusion, we present an accurate assay for the diagnosis and monitoring of EOC via CTC RNA analysis, and the results suggest that it may provide a promising solution for the detection and treatment response assessment of EOC.


  • Selection of DNA aptamer recognizing CD44 for high-efficiency capture of circulating tumor cells

    by Tian Gao, Wenjing Li, Jialing Ma, Ying Chen, Zhili Wang, Na Sun, Renjun Pei


  • Dengue determinants: Necessities and challenges for universal dengue vaccine development

    by Zahid Hussain, Saima Rani, Fanshu Ma, Wenjing Li, Wenqi Shen, Tian Gao, Jine Wang, Renjun Pei

    Dengue illness can range from mild illness to life‐threatening haemorrhage. It is an Aedes‐borne infectious disease caused by the dengue virus, which has four serotypes. Each serotype acts as an independent infectious agent. The antibodies against one serotype confer homotypic immunity but temporary protection against heterotypic infection. Dengue has become a growing health concern for up to one third of the world's population. Currently, there is no potent anti‐dengue medicine, and treatment for severe dengue relies on intravenous fluid management and pain medications. The burden of dengue dramatically increases despite advances in vector control measures. These factors underscore the need for a vaccine. Various dengue vaccine strategies have been demonstrated, that is, live attenuated vaccine, inactivated vaccine, DNA vaccine, subunit vaccine, and viral‐vector vaccines, some of which are at the stage of clinical testing. Unfortunately, the forefront candidate vaccine is less than satisfactory, and its performance depends on serostatus and age factors. The lessons from clinical studies depicted ambiguity concerning the efficacy of dengue vaccine. Our study highlighted that viral structural heterogeneity, epitope accessibility, autoimmune complications, genetic variants, genetic diversities, antigen competition, virulence variation, host‐pathogen specific interaction, antibody‐dependent enhancement, cross‐reactive immunity among Flaviviruses, and host‐susceptibility determinants not only influence infection outcomes but also hampered successful vaccine development. This review integrates dengue determinants allocated necessities and challenges, which would provide insight for universal dengue vaccine development.


  • Open Access

    Clinical features and therapeutic outcomes of alveolar soft part sarcoma in children: A single-center, retrospective study

    by Zhichao Tan, Jiayong Liu, Ruifeng Xue, Zhengfu Fan, Chujie Bai, Shu Li, Tian Gao, Lu Zhang, Xinyu Wang

    Background: Alveolar soft part sarcoma (ASPS) is a rare sarcoma that has been shown to be highly effective to antiangiogenic agents and immune checkpoint inhibitors, but most reported studies about ASPS were concentrated on adult population. In this study, we aimed to describe the clinical features and therapeutic outcomes of ASPS in children.Methods: We retrospectively reviewed the records of patients with ASPS in our institution since Jan 2015. All patients included in this study were pathologically confirmed ASPS and aged under 12 years at the time of initial diagnosis. Demographic characteristics, tumor sizes, primary tumor sites, metastasis, treatments used, therapeutic responses and survivals were evaluated.Results: We identified a total of 56 patients to be initially diagnosed as ASPS since Jan 2015. A predisposition of high occurrence in head and neck (32.1%) was observed (versus 41.1% in limbs and 21.4% in trunk). 26 (46.4%) patients developed metastasis at the time of diagnosis or during follow-up. Tumors in tongue, pharynx and larynx had the least likelihood to metastasize (7.7%, P<0.05). Observation was recommended for 15 stage IV patients with only pulmonary metastasis. 7 (46.7%) patients remained stable until last follow up. The 1-year PFS rate was 83.3% and median progression-free survival time (PFS) was 29.4 months. 15 patients with progressive disease received mono or combined therapy. 11 patients received PD-1 monotherapy. 2 patients achieved partial response and 5 stable disease. The overall response rate was 18.2%. The median PFS of this group was 22.0 months, and the 1-year PFS rate was 70.0%. 4 patients received a combination therapy of PD-1 inhibitors plus tyrosine kinase inhibitors. All of them remained stable. No disease-related death occurred during follow-up.Conclusions: ASPS exhibits a higher occurrence in head and neck in children. ASPS originating from glossopharyngeal region tends to have a lower metastasis rate. ASPS displays a more indolent growth pattern in children, which makes observation a preferable choice for children with sole pulmonary metastasis. Pediatric ASPS appears to be less effective to targeted therapy and immunotherapy than adults. The treatment of progressive ASPS in children remains challenging.


  • Open Access

    Cancer-associated fibroblast-targeted nanodrugs reshape colorectal tumor microenvironments to suppress tumor proliferation, metastasis and improve drug penetration

    by Wenqi Shen, Ping-An Yao, Wenjing Li, Changji Gu, Tian Gao, Yi Cao, Zheng Wang, Renjun Pei, Chungen Xing

    Cancer-associated fibroblasts (CAFs) produce a critical tumor-promoting effect by cellular crosstalk with cancer cells and remodel the extracellular matrix (ECM) to form a protective physical barrier. The simple elimination of CAFs is not sufficient to govern the CAF-shaped aggressive tumor microenvironment (TME) because of the complexity of tumors. Herein, a CAF-targeted poly (lactic-co-glycolic acid) (PLGA) nanoemulsion is tailored to simultaneously deliver doxorubicin (DOX) and small interfering RNA (siRNA) targeting hepatocyte growth factor (HGF) for the combination of chemotherapy and gene therapy. The nanoemulsion (apt-Si/DNPs) shows a high specificity towards CAFs due to the aptamer modification and efficiently induces the apoptosis of CAFs, thus decreasing ECM deposition in the TME. Importantly, the delivered siRNA reduces the expression of the HGF in the remaining CAFs, which overcomes chemotherapy-induced upregulation of HGF mRNA and prevents the reproduction of CAFs through the autocrine HGF closed-loop. Owing to these synergetic effects, tumor proliferation, migration and invasion are prominently inhibited and tumor permeability is improved significantly. Overall, these results emphasize the potential of CAF-targeted combination treatments to inhibit tumor progression and metastasis, as well as overcome therapeutic resistance.


  • Selection of CD133-targeted DNA aptamers for the efficient and specific therapy of colorectal cancer

    by Wenjing Li, Zheng Wang, Tian Gao, Shengkai Sun, Mingsheng Xu, Renjun Pei

    Tumor-targeted delivery of antitumor drugs is considered a promising strategy for improving the chemotherapeutic efficiency and reducing the incidence of side effects. The development of tumor-targeted aptamers to accommodate drugs has attracted great interest because of their convenience in biomedical applications. CD133 is a robust biomarker of colorectal cancer. In this study, Cs5, a novel specific aptamer with a dissociation constant in the nanomolar range, was developed using the cell-SELEX strategy from engineered CD133-expressing cells, and doxorubicin (Dox) was loaded into the Cs5 aptamer to form a chimera. The chimera showed an excellent targeting ability for CD133 through a selective killing effect in human colorectal cancer HCT116 cells expressing CD133. The in vitro and in vivo results demonstrated the highly efficient therapy and low toxicity of the chimera. Given the overexpression of CD133 in various tumors, our work provides a promising tool for specific cell identification and a wide range of applications in the field of targeted cancer therapy.


  • Aptamer-Targeted Photodynamic Platforms for Tumor Therapy

    by Jincong Yan, Tian Gao, Zhongzhong Lu, Jingbo Yin, Ye Zhang, Renjun Pei

    Achieving controlled and accurate delivery of photosensitizers (PSs) into tumor sites is a major challenge in conventional photodynamic therapy (PDT). Aptamer is a short oligonucleotide sequence (DNA or RNA) with a folded three-dimensional structure, which can selectively bind to specific small molecules, proteins, or the whole cells. Aptamers could act as ligands and be modified onto PSs or nanocarriers, enabling specific recognition and binding to tumor cells or their membrane proteins. The resultant aptamer-modified PSs or PSs-containing nanocarriers generate amounts of reactive oxygen species with light irradiation and obtain superior photodynamic therapeutic efficiency in tumors. Herein, we overview the recent progress in the designs and applications of aptamer-targeted photodynamic platforms for tumor therapy. First, we focus on the progress on the rational selection of aptamers and summarize the applications of aptamers which have been applied for targeted tumor diagnosis and therapy. Then, aptamer-targeted photodynamic therapies including various aptamer–PSs, aptamer–nanocarriers containing PSs, and aptamer–nano-photosensitizers are highlighted. The aptamer-targeted synergistically therapeutic platforms including PDT, photothermal therapy, and chemotherapy, as well as the imaging-guided theranostics, are also discussed. Finally, we offer an insight into the development trends and future perspectives of aptamer-targeted photodynamic platforms for tumor therapy.


  • A PLGA nanofiber microfluidic device for highly efficient isolation and release of different phenotypic circulating tumor cells based on dual aptamers

    by Zeen Wu, Yue Pan, Zhili Wang, Pi Ding, Tian Gao, Qing Li, Mingchao Hu, Weipei Zhu, Renjun Pei

    The isolation of specific and sensitive circulating tumor cells (CTCs) is significant for applying them in cancer diagnosis and monitoring. In this work, dual aptamer-modified poly(lactic-co-glycolic acid) (PLGA) nanofiber-based microfluidic devices were fabricated to achieve the highly efficient capture and specific release of epithelial and mesenchymal CTCs of ovarian cancer. Dual aptamer targeting epithelial cell adhesion molecules (EpCAM) and N-cadherin proteins to improve the capture sensitivity, bovine serum albumin (BSA) to guarantee the capture purity and the nanofibers to increase the capture efficiency via synchronously and effectively capturing the epithelial and mesenchymal CTCs with good capture specificity and sensitivity from blood samples were used. We used the target cells including the ovarian cancer A2780 cells (N-cadherin-high, EpCAM-low) and OVCAR-3 cells (EpCAM-high, N-cadherin-low) to test the devices, which exhibited good capture efficiency (91% for A2780 cells, 89% for OVCAR-3 cells), release efficiency (95% for A2780 cells, 88% for OVCAR-3 cells), and sensitivity for rare cells (92% for A2780 cells, 88% for OVCAR-3 cells). Finally, the clinical blood samples of ovarian cancer patients were detected by the PLGA nanofiber-based microfluidic device, and 1 to 13 CTCs were successfully confirmed to be captured with the help of immunofluorescence staining identification. The results exhibited that the dual aptamer-modified PLGA nanofiber-based microfluidic device used as a tool for CTC capture has the potential for clinical application to guide the diagnosis, treatment, and prognosis of ovarian cancer patients.